<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20230817100713&amp;utm_campaign=pubmed-2&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20230817100713&amp;utm_campaign=pubmed-2&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 17 Aug 2023 14:07:14 +0000</lastbuilddate>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Endothelial FIS1 DeSUMOylation Protects Against Hypoxic Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37589160/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: By maintaining endothelial mitochondrial homeostasis, deSUMOylation of FIS1 adaptively preserves pulmonary endothelial function against hypoxic stress and consequently protects against PH. The FIS1 deSUMOylation-SUMOylation transition in pulmonary endothelium is an intrinsic pathogenesis of hypoxic PH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 17. doi: 10.1161/CIRCRESAHA.122.321200. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypoxia is a major cause and promoter of pulmonary hypertension (PH), a representative vascular remodeling disease with poor prognosis and high mortality. However, the mechanism underlying how pulmonary arterial system responds to hypoxic stress during PH remains unclear. Endothelial mitochondria are considered signaling organelles on oxygen tension. Results from previous clinical research and our studies suggested a potential role of posttranslational SUMOylation in endothelial mitochondria in hypoxia-related vasculopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Chronic hypoxia mouse model and Sugen/hypoxia rat model were employed as PH animal models. Mitochondrial morphology and subcellular structure were determined by transmission electron and immunofluorescent microscopies. Mitochondrial metabolism was determined by mitochondrial oxygen consumption rate and extracellular acidification rate. SUMOylation and protein interaction were determined by immunoprecipitation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The involvement of SENP1 (sentrin-specific protease 1)-mediated SUMOylation in mitochondrial remodeling in the pulmonary endothelium was identified in clinical specimens of hypoxia-related PH and was verified in human pulmonary artery endothelial cells under hypoxia. Further analyses in clinical specimens, hypoxic rat and mouse PH models, and human pulmonary artery endothelial cells and human embryonic stem cell-derived endothelial cells revealed that short-term hypoxia-induced SENP1 translocation to endothelial mitochondria to regulate deSUMOylation of mitochondrial fission protein FIS1 (mitochondrial fission 1), which facilitated FIS1 assembling with fusion protein MFN2 (mitofusin 2) and mitochondrial gatekeeper VDAC1 (voltage-dependent anion channel 1), and the membrane tethering activity of MFN2 by enhancing its oligomerization. Consequently, FIS1 deSUMOylation maintained the mitochondrial integrity and endoplasmic reticulum-mitochondria calcium communication across mitochondrial-associated membranes, subsequently preserving pulmonary endothelial function and vascular homeostasis. In contrast, prolonged hypoxia disabled the FIS1 deSUMOylation by diminishing the availability of SENP1 in mitochondria via inducing miR-138 and consequently resulted in mitochondrial dysfunction and metabolic reprogramming in pulmonary endothelium. Functionally, introduction of viral-packaged deSUMOylated FIS1 within pulmonary endothelium in mice improved pulmonary endothelial dysfunction and hypoxic PH development, while knock-in of SUMO (small ubiquitin-like modifier)-conjugated FIS1 in mice exaggerated the diseased cellular and tissue phenotypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: By maintaining endothelial mitochondrial homeostasis, deSUMOylation of FIS1 adaptively preserves pulmonary endothelial function against hypoxic stress and consequently protects against PH. The FIS1 deSUMOylation-SUMOylation transition in pulmonary endothelium is an intrinsic pathogenesis of hypoxic PH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37589160/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37589160</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.122.321200>10.1161/CIRCRESAHA.122.321200</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37589160</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Xiaofei Zhou</dc:creator>
<dc:creator>Yuanqing Jiang</dc:creator>
<dc:creator>Yuewen Wang</dc:creator>
<dc:creator>Linge Fan</dc:creator>
<dc:creator>Yunhui Zhu</dc:creator>
<dc:creator>Yefeng Chen</dc:creator>
<dc:creator>Yiran Wang</dc:creator>
<dc:creator>Yingyi Zhu</dc:creator>
<dc:creator>Hongkun Wang</dc:creator>
<dc:creator>Zihang Pan</dc:creator>
<dc:creator>Zhoubin Li</dc:creator>
<dc:creator>Xiaolong Zhu</dc:creator>
<dc:creator>Ruizhe Ren</dc:creator>
<dc:creator>Zhen Ge</dc:creator>
<dc:creator>Dongwu Lai</dc:creator>
<dc:creator>En-Yin Lai</dc:creator>
<dc:creator>Ting Chen</dc:creator>
<dc:creator>Kai Wang</dc:creator>
<dc:creator>Ping Liang</dc:creator>
<dc:creator>Lingfeng Qin</dc:creator>
<dc:creator>Cuiqing Liu</dc:creator>
<dc:creator>Cong Qiu</dc:creator>
<dc:creator>Michael Simons</dc:creator>
<dc:creator>Luyang Yu</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Endothelial FIS1 DeSUMOylation Protects Against Hypoxic Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:37589160</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.122.321200</dc:identifier>
</item>
<item>
<title>Extravalvular Myocardial Damage and Aortic Valve Replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587588/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):e67. doi: 10.1016/j.jacc.2023.04.061.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587588/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587588</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.04.061>10.1016/j.jacc.2023.04.061</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587588</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ahmed Elkaryoni</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Extravalvular Myocardial Damage and Aortic Valve Replacement</dc:title>
<dc:identifier>pmid:37587588</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.04.061</dc:identifier>
</item>
<item>
<title>Long-Term Clinical Consequences of Right Ventricular Remodeling in Olympic Endurance Athletes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587587/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):750-751. doi: 10.1016/j.jacc.2023.04.060.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587587/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587587</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.04.060>10.1016/j.jacc.2023.04.060</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587587</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Antonio Pelliccia</dc:creator>
<dc:creator>Roberto Ferrara</dc:creator>
<dc:creator>Silvia Prosperi</dc:creator>
<dc:creator>Antonio Spataro</dc:creator>
<dc:creator>Viviana Maestrini</dc:creator>
<dc:creator>Maria Rosaria Squeo</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Clinical Consequences of Right Ventricular Remodeling in Olympic Endurance Athletes</dc:title>
<dc:identifier>pmid:37587587</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.04.060</dc:identifier>
</item>
<item>
<title>Challenges to Science, Health, and Education as Contributors to Progress: A Call to the Young Generation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587586/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):748-749. doi: 10.1016/j.jacc.2023.07.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587586/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587586</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.002>10.1016/j.jacc.2023.07.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587586</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Valentin Fuster</dc:creator>
<dc:creator>Justine Varieur Turco</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Challenges to Science, Health, and Education as Contributors to Progress: A Call to the Young Generation</dc:title>
<dc:identifier>pmid:37587586</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.002</dc:identifier>
</item>
<item>
<title>Risk of Arrhythmic Death in Patients With Nonischemic Cardiomyopathy: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587585/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>Nonischemic cardiomyopathy (NICM) is common and patients are at significant risk for early mortality secondary to ventricular arrhythmias. Current guidelines recommend implantable cardioverter-defibrillator (ICD) therapy to decrease sudden cardiac death (SCD) in patients with heart failure and reduced left ventricular ejection fraction. However, in randomized clinical trials comprised solely of patients with NICM, primary prevention ICDs did not confer significant mortality benefit. Moreover,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):735-747. doi: 10.1016/j.jacc.2023.05.064.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Nonischemic cardiomyopathy (NICM) is common and patients are at significant risk for early mortality secondary to ventricular arrhythmias. Current guidelines recommend implantable cardioverter-defibrillator (ICD) therapy to decrease sudden cardiac death (SCD) in patients with heart failure and reduced left ventricular ejection fraction. However, in randomized clinical trials comprised solely of patients with NICM, primary prevention ICDs did not confer significant mortality benefit. Moreover, left ventricular ejection fraction has limited sensitivity and specificity for predicting SCD. Therefore, precise risk stratification algorithms are needed to define those at the highest risk of SCD. This review examines mechanisms of sudden arrhythmic death in patients with NICM, discusses the role of ICD therapy and treatment of heart failure for prevention of SCD in patients with NICM, examines the role of cardiac magnetic resonance imaging and computational modeling for SCD risk stratification, and proposes new strategies to guide future clinical trials on SCD risk assessment in patients with NICM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587585/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587585</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.064>10.1016/j.jacc.2023.05.064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587585</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jonathan Chrispin</dc:creator>
<dc:creator>Faisal M Merchant</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Katherine C Wu</dc:creator>
<dc:creator>Gordon F Tomaselli</dc:creator>
<dc:creator>Rachita Navara</dc:creator>
<dc:creator>Estelle Torbey</dc:creator>
<dc:creator>Amrut V Ambardekar</dc:creator>
<dc:creator>Rajesh Kabra</dc:creator>
<dc:creator>Eloisa Arbustini</dc:creator>
<dc:creator>Jagat Narula</dc:creator>
<dc:creator>Maya Guglin</dc:creator>
<dc:creator>Christine M Albert</dc:creator>
<dc:creator>Sumeet S Chugh</dc:creator>
<dc:creator>Natalia Trayanova</dc:creator>
<dc:creator>Jim W Cheung</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Risk of Arrhythmic Death in Patients With Nonischemic Cardiomyopathy: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37587585</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.064</dc:identifier>
</item>
<item>
<title>ACC/AHA and ESC/EACTS Guidelines for the Management of Valvular Heart Diseases: JACC Guideline Comparison</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587584/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>Valvular heart disease (VHD) is common and poses important challenges from the standpoints of diagnosis and therapeutic management. Clinical practice guidelines have been developed to help health care professionals to overcome these challenges and provide optimal management to patients with VHD. The American College of Cardiology, in collaboration with the American Heart Association, and the European Society of Cardiology, in collaboration with the European Association for Cardio-Thoracic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):721-734. doi: 10.1016/j.jacc.2023.05.061.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Valvular heart disease (VHD) is common and poses important challenges from the standpoints of diagnosis and therapeutic management. Clinical practice guidelines have been developed to help health care professionals to overcome these challenges and provide optimal management to patients with VHD. The American College of Cardiology, in collaboration with the American Heart Association, and the European Society of Cardiology, in collaboration with the European Association for Cardio-Thoracic Surgery, recently updated their guidelines on the management of VHD. Although these 2 sets of guidelines are generally concordant, there are some substantial differences between these guidelines, which may have significant implications for clinical practice. This review prepared on behalf of the EuroValve Consortium describes the consistencies and discrepancies between the guidelines and highlights the gaps in these guidelines and the future research perspectives to fill these gaps.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587584/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587584</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.061>10.1016/j.jacc.2023.05.061</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587584</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Augustin Coisne</dc:creator>
<dc:creator>Patrizio Lancellotti</dc:creator>
<dc:creator>Gilbert Habib</dc:creator>
<dc:creator>Madalina Garbi</dc:creator>
<dc:creator>Jordi Sanchez Dahl</dc:creator>
<dc:creator>Marco Barbanti</dc:creator>
<dc:creator>Mani A Vannan</dc:creator>
<dc:creator>Vassilios S Vassiliou</dc:creator>
<dc:creator>Dariusz Dudek</dc:creator>
<dc:creator>Ovidiu Chioncel</dc:creator>
<dc:creator>Johannes L Waltenberger</dc:creator>
<dc:creator>Victoria L Johnson</dc:creator>
<dc:creator>Ruggero De Paulis</dc:creator>
<dc:creator>Rodolfo Citro</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>EuroValve Consortium</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>ACC/AHA and ESC/EACTS Guidelines for the Management of Valvular Heart Diseases: JACC Guideline Comparison</dc:title>
<dc:identifier>pmid:37587584</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.061</dc:identifier>
</item>
<item>
<title>Right Atrium as Barometer of Right Ventricular Stiffness and Treatment Responsiveness in Precapillary Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587583/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):718-720. doi: 10.1016/j.jacc.2023.06.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587583/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587583</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.009>10.1016/j.jacc.2023.06.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587583</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Maria Rosa Costanzo</dc:creator>
<dc:creator>Thomas H Marwick</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Right Atrium as Barometer of Right Ventricular Stiffness and Treatment Responsiveness in Precapillary Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:37587583</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.009</dc:identifier>
</item>
<item>
<title>Right Atrial Adaptation to Precapillary Pulmonary Hypertension: Pressure-Volume, Cardiomyocyte, and Histological Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587582/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: RA PV loops show increased RA stiffness and suggest atrioventricular uncoupling in patients with severe RV diastolic stiffness. Isolated RA cardiomyocytes of precPH patients are hypertrophied, without intrinsic sarcomeric changes. In end-stage precPH, reduced capillary density is accompanied by interstitial and perivascular fibrosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):704-717. doi: 10.1016/j.jacc.2023.05.063.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Precapillary pulmonary hypertension (precPH) patients have altered right atrial (RA) function and right ventricular (RV) diastolic stiffness.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to investigate RA function using pressure-volume (PV) loops, isolated cardiomyocyte, and histological analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: RA PV loops were constructed in control subjects (n = 9) and precPH patients (n = 27) using magnetic resonance and catheterization data. RA stiffness (pressure rise during atrial filling) and right atrioventricular coupling index (RA minimal volume / RV end-diastolic volume) were compared in a larger cohort of patients with moderate (n = 39) or severe (n = 41) RV diastolic stiffness. Cardiomyocytes were isolated from RA tissue collected from control subjects (n = 6) and precPH patients (n = 9) undergoing surgery. Autopsy material was collected from control subjects (n = 6) and precPH patients (n = 4) to study RA hypertrophy, capillarization, and fibrosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: RA PV loops showed 3 RA cardiac phases (reservoir, passive emptying, and contraction) with dilatation and elevated pressure in precPH. PrecPH patients with severe RV diastolic stiffness had increased RA stiffness and worse right atrioventricular coupling index. Cardiomyocyte cross-sectional area was increased 2- to 3-fold in precPH, but active tension generated by the sarcomeres was unaltered. There was no increase in passive tension of the cardiomyocytes, but end-stage precPH showed reduced number of capillaries per mm<sup>2</sup> accompanied by interstitial and perivascular fibrosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: RA PV loops show increased RA stiffness and suggest atrioventricular uncoupling in patients with severe RV diastolic stiffness. Isolated RA cardiomyocytes of precPH patients are hypertrophied, without intrinsic sarcomeric changes. In end-stage precPH, reduced capillary density is accompanied by interstitial and perivascular fibrosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587582/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587582</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.063>10.1016/j.jacc.2023.05.063</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587582</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jeroen N Wessels</dc:creator>
<dc:creator>Jessie van Wezenbeek</dc:creator>
<dc:creator>Jari de Rover</dc:creator>
<dc:creator>Rowan Smal</dc:creator>
<dc:creator>Aida Llucià-Valldeperas</dc:creator>
<dc:creator>Lucas R Celant</dc:creator>
<dc:creator>J Tim Marcus</dc:creator>
<dc:creator>Lilian J Meijboom</dc:creator>
<dc:creator>Joanne A Groeneveldt</dc:creator>
<dc:creator>Frank P T Oosterveer</dc:creator>
<dc:creator>Toon A Winkelman</dc:creator>
<dc:creator>Hans W M Niessen</dc:creator>
<dc:creator>Marie-José Goumans</dc:creator>
<dc:creator>Harm Jan Bogaard</dc:creator>
<dc:creator>Anton Vonk Noordegraaf</dc:creator>
<dc:creator>Gustav J Strijkers</dc:creator>
<dc:creator>M Louis Handoko</dc:creator>
<dc:creator>Berend E Westerhof</dc:creator>
<dc:creator>Frances S de Man</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Right Atrial Adaptation to Precapillary Pulmonary Hypertension: Pressure-Volume, Cardiomyocyte, and Histological Analysis</dc:title>
<dc:identifier>pmid:37587582</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.063</dc:identifier>
</item>
<item>
<title>Is Risk Stratification for Bleeding and Ischemic Events Still Useful When De-Escalating to Ticagrelor Monotherapy?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587581/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):701-703. doi: 10.1016/j.jacc.2023.06.010.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587581/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587581</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.010>10.1016/j.jacc.2023.06.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587581</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Puja B Parikh</dc:creator>
<dc:creator>Tullio Palmerini</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Is Risk Stratification for Bleeding and Ischemic Events Still Useful When De-Escalating to Ticagrelor Monotherapy?</dc:title>
<dc:identifier>pmid:37587581</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.010</dc:identifier>
</item>
<item>
<title>Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587580/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Three months after PCI, discontinuing aspirin and maintaining ticagrelor monotherapy reduces bleeding in both higher-bleeding risk and lower-bleeding risk patients compared with continued DAPT. This benefit does not appear to be offset by greater ischemic risk. (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention [TWILIGHT]; NCT02270242).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):687-700. doi: 10.1016/j.jacc.2023.05.062.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention), among high-risk patients undergoing percutaneous coronary intervention (PCI), ticagrelor monotherapy vs continuation of dual antiplatelet therapy (DAPT) with aspirin and ticagrelor after completing a 3-month course of DAPT was associated with reduced bleeding, without an increase in ischemic events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This investigation sought to study the clinical benefit of ticagrelor monotherapy vs DAPT by simultaneously modeling its associated potential bleeding benefits and ischemic harms on an individual patient basis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Multivariable Cox regression models for: 1) Bleeding Academic Research Consortium type 2, 3, or 5 (BARC-2/3/5); and 2) cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke (major adverse cardiac and cerebrovascular event [MACCE]) were developed using stepwise forward variable selection. The coefficients in the BARC-2/3/5 and MACCE models were used to calculate bleeding and ischemic risk scores, respectively, for each patient (excluding the coefficient for randomized treatment).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the total study group (N = 7,119), BARC-2/3/5 occurred in 391 (5.5%) patients, and MACCE occurred in 258 (3.6%). There was a consistent reduction in bleeding events associated with ticagrelor monotherapy compared with DAPT across both bleeding and ischemic risk strata (P interaction = 0.54 and 0.11, respectively). Importantly, this benefit associated with ticagrelor monotherapy was not offset by an increase in MACCE at any level of bleeding or ischemic risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Three months after PCI, discontinuing aspirin and maintaining ticagrelor monotherapy reduces bleeding in both higher-bleeding risk and lower-bleeding risk patients compared with continued DAPT. This benefit does not appear to be offset by greater ischemic risk. (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention [TWILIGHT]; NCT02270242).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587580/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587580</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.062>10.1016/j.jacc.2023.05.062</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587580</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Guiomar Mendieta</dc:creator>
<dc:creator>Shamir Mehta</dc:creator>
<dc:creator>Usman Baber</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Carlo Briguori</dc:creator>
<dc:creator>David Cohen</dc:creator>
<dc:creator>Timothy Collier</dc:creator>
<dc:creator>George Dangas</dc:creator>
<dc:creator>Dariusz Dudek</dc:creator>
<dc:creator>Javier Escaned</dc:creator>
<dc:creator>Robert Gil</dc:creator>
<dc:creator>Birgit Vogel</dc:creator>
<dc:creator>Davide Cao</dc:creator>
<dc:creator>Alessandro Spirito</dc:creator>
<dc:creator>Kurt Huber</dc:creator>
<dc:creator>Adnan Kastrati</dc:creator>
<dc:creator>Upendra Kaul</dc:creator>
<dc:creator>Ran Kornowski</dc:creator>
<dc:creator>Mitchell W Krucoff</dc:creator>
<dc:creator>Vijay Kunadian</dc:creator>
<dc:creator>David J Moliterno</dc:creator>
<dc:creator>E Magnus Ohman</dc:creator>
<dc:creator>Gennaro Sardella</dc:creator>
<dc:creator>Samantha Sartori</dc:creator>
<dc:creator>Samin Sharma</dc:creator>
<dc:creator>Richard Shlofmitz</dc:creator>
<dc:creator>P Gabriel Steg</dc:creator>
<dc:creator>Ya-Ling Han</dc:creator>
<dc:creator>Stuart Pocock</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions</dc:title>
<dc:identifier>pmid:37587580</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.062</dc:identifier>
</item>
<item>
<title>Long-Duration Space Flight and Cardiac Morphology: To Boldly Go Where No Man Has Gone Before</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587579/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):685-686. doi: 10.1016/j.jacc.2023.06.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587579/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587579</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.030>10.1016/j.jacc.2023.06.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587579</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Carl L Tommaso</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Duration Space Flight and Cardiac Morphology: To Boldly Go Where No Man Has Gone Before</dc:title>
<dc:identifier>pmid:37587579</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.030</dc:identifier>
</item>
<item>
<title>Cardiac Effects of Long-Duration Space Flight</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587578/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The current exercise countermeasures used on the ISS appear effective in offsetting reductions in cardiac mass and volume, despite overall reductions in total cardiac work, during prolonged space flight.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):674-684. doi: 10.1016/j.jacc.2023.05.058.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Ventricular mass responds to changes in physical activity and loading, with cardiac hypertrophy after exercise training, and cardiac atrophy after sustained inactivity. Ventricular wall stress (ie, loading) decreases during microgravity. Cardiac atrophy does not plateau during 12 weeks of simulated microgravity but is mitigated by concurrent exercise training.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to determine whether the current exercise countermeasures on the International Space Station (ISS) offset cardiac atrophy during prolonged space flight.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We measured left ventricular (LV) and right ventricular (RV) mass and volumes (via magnetic resonance imaging) in 13 astronauts (4 females; age 49 ± 4 years), between 75 and 60 days before and 3 days after 155 ± 31 days aboard the ISS. Furthermore, we assessed total cardiac work between 21 and 7 days before space flight and 15 days before the end of the mission. Data were compared via paired-samples t-tests.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Total cardiac work was lower during space flight (P = 0.008); however, we observed no meaningful difference in LV mass postflight (pre: 115 ± 30 g vs post: 118 ± 29 g; P = 0.053), with marginally higher LV stroke volume (P = 0.074) and ejection fraction postflight (P = 0.075). RV mass (P = 0.999), RV ejection fraction (P = 0.147), and ventricular end-diastolic (P = 0.934) and end-systolic volumes (P = 0.145) were not different postflight. There were strong positive correlations between the relative change in LV mass with the relative changes in total cardiac output (r = 0.73; P = 0.015) and total cardiac work (r = 0.53; P = 0.112).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The current exercise countermeasures used on the ISS appear effective in offsetting reductions in cardiac mass and volume, despite overall reductions in total cardiac work, during prolonged space flight.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587578/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587578</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.058>10.1016/j.jacc.2023.05.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587578</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Shigeki Shibata</dc:creator>
<dc:creator>Denis J Wakeham</dc:creator>
<dc:creator>James D Thomas</dc:creator>
<dc:creator>Shuaib M Abdullah</dc:creator>
<dc:creator>Steven Platts</dc:creator>
<dc:creator>Michael W Bungo</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac Effects of Long-Duration Space Flight</dc:title>
<dc:identifier>pmid:37587578</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.058</dc:identifier>
</item>
<item>
<title>Competitive Sports Participation for Athletes With Genetic Heart Disease: A Whole New Ballgame</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587577/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):671-673. doi: 10.1016/j.jacc.2023.05.060.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587577/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587577</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.060>10.1016/j.jacc.2023.05.060</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587577</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Competitive Sports Participation for Athletes With Genetic Heart Disease: A Whole New Ballgame</dc:title>
<dc:identifier>pmid:37587577</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.060</dc:identifier>
</item>
<item>
<title>Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This is the first study describing the experience of athletes with a known SCD-predisposing GHD who are competing at the elite level. After careful evaluation, risk stratification, and tailoring of their GHD therapy, RTP following SDM appears associated with low, nonfatal events rates at elite levels of sport.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 22;82(8):661-670. doi: 10.1016/j.jacc.2023.05.059.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: People diagnosed with genetic heart diseases (GHDs) associated with sudden cardiac death (SCD) have historically been restricted from competitive sports. Recent data documenting return-to-play (RTP) experiences following shared decision making (SDM) suggest that cardiac event rates for athletes with a GHD are lower than previously described, thereby suggesting an opportunity to reconsider this paradigm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to evaluate clinical outcomes among National Collegiate Athletic Association Division I university and professional athletes diagnosed with a GHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A multicenter retrospective analysis was performed to examine demographics, clinical characteristics, RTP outcomes, and cardiac events among elite athletes with a GHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 76 elite (66%, Division I, 34% professional) athletes (age 19.9 ± 5 years, 28% women) diagnosed with a GHD (hypertrophic cardiomyopathy [53%], long QT syndrome, long QT syndrome [26%]) comprise this cohort. Most athletes were asymptomatic (48 of 76, 63%) before diagnosis and had their GHD detected during routine preparticipation cardiovascular screening. Most athletes (55 of 76, 72%) were initially disqualified from their sport but subsequently opted for unrestricted RTP after comprehensive clinical evaluation and SDM. To date, (mean follow-up 7 ± 6 years), only 1 exercise-related (1.3%) and 2 nonexercise-related GHD-associated adverse cardiac events occurred. There have been no fatalities during follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This is the first study describing the experience of athletes with a known SCD-predisposing GHD who are competing at the elite level. After careful evaluation, risk stratification, and tailoring of their GHD therapy, RTP following SDM appears associated with low, nonfatal events rates at elite levels of sport.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587576</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.059>10.1016/j.jacc.2023.05.059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587576</guid>
<pubDate>Thu, 17 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Katherine A Martinez</dc:creator>
<dc:creator>J Martijn Bos</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Dermot M Phelan</dc:creator>
<dc:creator>Kathryn E Tobert</dc:creator>
<dc:creator>Darrel B Newman</dc:creator>
<dc:creator>Erica Scherer</dc:creator>
<dc:creator>Bradley J Petek</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:date>2023-08-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death</dc:title>
<dc:identifier>pmid:37587576</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.059</dc:identifier>
</item>
<item>
<title>Future research with advanced imaging technology and biomarkers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 17:ehad530. doi: 10.1093/eurheartj/ehad530. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587554/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587554</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad530>10.1093/eurheartj/ehad530</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587554</guid>
<pubDate>Wed, 16 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Fabrizio Montecucco</dc:creator>
<dc:creator>Thomas H Schindler</dc:creator>
<dc:date>2023-08-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Future research with advanced imaging technology and biomarkers</dc:title>
<dc:identifier>pmid:37587554</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad530</dc:identifier>
</item>
<item>
<title>Inflammation in acute myocardial infarction: the good, the bad and the ugly</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587550/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies on cardiovascular outcomes by targeting the residual inflammatory risk (RIR), i.e. the smouldering...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 17:ehad486. doi: 10.1093/eurheartj/ehad486. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies on cardiovascular outcomes by targeting the residual inflammatory risk (RIR), i.e. the smouldering ember of low-grade inflammation persisting in the late phase after AMI. However, these studies have also taught us about potential risks of anti-inflammatory therapy after AMI, particularly related to impaired host defence. Recently, numerous smaller-scale trials have addressed the concept of targeting a deleterious flare of excessive inflammation in the early phase after AMI. Targeting different pathways and implementing various treatment regimens, those trials have met with varied degrees of success. Promising results have come from those studies intervening early on the interleukin-1 and -6 pathways. Taking lessons from such past research may inform an optimized approach to target post-AMI inflammation, tailored to spare 'The Good' (repair and defence) while treating 'The Bad' (smouldering RIR) and capturing 'The Ugly' (flaming early burst of excess inflammation in the acute phase). Key constituents of such a strategy may read as follows: select patients with large pro-inflammatory burden (i.e. large AMI); initiate treatment early (e.g. ≤12 h post-AMI); implement a precisely targeted anti-inflammatory agent; follow through with a tapering treatment regimen. This approach warrants testing in rigorous clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587550/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587550</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad486>10.1093/eurheartj/ehad486</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587550</guid>
<pubDate>Wed, 16 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael A Matter</dc:creator>
<dc:creator>Francesco Paneni</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Stefan Frantz</dc:creator>
<dc:creator>Barbara E Stähli</dc:creator>
<dc:creator>Christian Templin</dc:creator>
<dc:creator>Alessandro Mengozzi</dc:creator>
<dc:creator>Yu-Jen Wang</dc:creator>
<dc:creator>Thomas M Kündig</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:creator>Frank Ruschitzka</dc:creator>
<dc:creator>Christian M Matter</dc:creator>
<dc:date>2023-08-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inflammation in acute myocardial infarction: the good, the bad and the ugly</dc:title>
<dc:identifier>pmid:37587550</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad486</dc:identifier>
</item>
<item>
<title>Superiority of the Ross procedure over other valve substitutes in the paediatric population: this is only the beginning!</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587549/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 17:ehad461. doi: 10.1093/eurheartj/ehad461. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587549/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587549</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad461>10.1093/eurheartj/ehad461</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587549</guid>
<pubDate>Wed, 16 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Yves d'Udekem</dc:creator>
<dc:creator>Eiri Kisamori</dc:creator>
<dc:creator>Alyssia Venna</dc:creator>
<dc:date>2023-08-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Superiority of the Ross procedure over other valve substitutes in the paediatric population: this is only the beginning!</dc:title>
<dc:identifier>pmid:37587549</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad461</dc:identifier>
</item>
<item>
<title>Pitavastatin reduces cardiovascular events in patients with HIV infection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37587223/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Aug 16. doi: 10.1038/s41569-023-00920-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37587223/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37587223</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00920-z>10.1038/s41569-023-00920-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37587223</guid>
<pubDate>Wed, 16 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-08-16</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Pitavastatin reduces cardiovascular events in patients with HIV infection</dc:title>
<dc:identifier>pmid:37587223</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00920-z</dc:identifier>
</item>
<item>
<title>Archival single-cell genomics reveals persistent subclones during DCIS progression</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 10:S0092-8674(23)00802-4. doi: 10.1016/j.cell.2023.07.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27 FFPE samples from breast, lung, and prostate tumors stored for 3-31 years. Analysis of 10 patients with matched DCIS and cancers that recurred 2-16 years later show that many primary DCIS had already undergone whole-genome doubling and clonal diversification and that they shared genomic lineages with persistent subclones in the recurrences. Evolutionary analysis suggests that most DCIS cases in our cohort underwent an evolutionary bottleneck, and further identified chromosome aberrations in the persistent subclones that were associated with recurrence.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37586362</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.024>10.1016/j.cell.2023.07.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37586362</guid>
<pubDate>Wed, 16 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Kaile Wang</dc:creator>
<dc:creator>Tapsi Kumar</dc:creator>
<dc:creator>Junke Wang</dc:creator>
<dc:creator>Darlan Conterno Minussi</dc:creator>
<dc:creator>Emi Sei</dc:creator>
<dc:creator>Jianzhuo Li</dc:creator>
<dc:creator>Tuan M Tran</dc:creator>
<dc:creator>Aatish Thennavan</dc:creator>
<dc:creator>Min Hu</dc:creator>
<dc:creator>Anna K Casasent</dc:creator>
<dc:creator>Zhenna Xiao</dc:creator>
<dc:creator>Shanshan Bai</dc:creator>
<dc:creator>Lei Yang</dc:creator>
<dc:creator>Lorraine M King</dc:creator>
<dc:creator>Vandna Shah</dc:creator>
<dc:creator>Petra Kristel</dc:creator>
<dc:creator>Carolien L van der Borden</dc:creator>
<dc:creator>Jeffrey R Marks</dc:creator>
<dc:creator>Yuehui Zhao</dc:creator>
<dc:creator>Amado J Zurita</dc:creator>
<dc:creator>Ana Aparicio</dc:creator>
<dc:creator>Brian Chapin</dc:creator>
<dc:creator>Jie Ye</dc:creator>
<dc:creator>Jianjun Zhang</dc:creator>
<dc:creator>Don L Gibbons</dc:creator>
<dc:creator>Grand Challenge PRECISION Consortium</dc:creator>
<dc:creator>Ellinor Sawyer</dc:creator>
<dc:creator>Alastair M Thompson</dc:creator>
<dc:creator>Andrew Futreal</dc:creator>
<dc:creator>E Shelley Hwang</dc:creator>
<dc:creator>Jelle Wesseling</dc:creator>
<dc:creator>Esther H Lips</dc:creator>
<dc:creator>Nicholas E Navin</dc:creator>
<dc:date>2023-08-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Archival single-cell genomics reveals persistent subclones during DCIS progression</dc:title>
<dc:identifier>pmid:37586362</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.024</dc:identifier>
</item>
<item>
<title>Association of radiation dose to cardiac substructures with major ischaemic events following breast cancer radiotherapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37585426/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: Risk of major ischaemic events exist in the era of modern radiotherapy. LV V25 ≥ 4% appeared to be the optimum parameter and was superior to MHD in predicting major ischaemic events. This dose constraint could aid in achieving better heart protection in breast cancer radiotherapy, though a further validation study is warranted.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 16:ehad462. doi: 10.1093/eurheartj/ehad462. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients with left-sided breast cancer receive a higher mean heart dose (MHD) after radiotherapy, with subsequent risk of ischaemic heart disease. However, the optimum dosimetric predictor among cardiac substructures has not yet been determined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: This study retrospectively reviewed 2158 women with breast cancer receiving adjuvant radiotherapy. The primary endpoint was a major ischaemic event. The dose-volume parameters of each delineated cardiac substructure were calculated. The risk factors for major ischaemic events and the association between MHD and major ischaemic events were analysed by Cox regression. The optimum dose-volume predictors among cardiac substructures were explored in multivariable models by comparing performance metrics of each model. At a median follow-up of 7.9 years (interquartile range 5.6-10.8 years), 89 patients developed major ischaemic events. The cumulative incidence rate of major ischaemic events was significantly higher in left-sided disease (P = 0.044). Overall, MHD increased the risk of major ischaemic events by 6.2% per Gy (hazard ratio 1.062, 95% confidence interval 1.01-1.12; P = 0.012). The model containing the volume of the left ventricle receiving 25 Gy (LV V25) with the cut-point of 4% presented with the best goodness of fit and discrimination performance in left-sided breast cancer. Age, chronic kidney disease, and hyperlipidaemia were also significant risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Risk of major ischaemic events exist in the era of modern radiotherapy. LV V25 ≥ 4% appeared to be the optimum parameter and was superior to MHD in predicting major ischaemic events. This dose constraint could aid in achieving better heart protection in breast cancer radiotherapy, though a further validation study is warranted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37585426/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37585426</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad462>10.1093/eurheartj/ehad462</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37585426</guid>
<pubDate>Wed, 16 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Tzu-Yu Lai</dc:creator>
<dc:creator>Yu-Wen Hu</dc:creator>
<dc:creator>Ti-Hao Wang</dc:creator>
<dc:creator>Jui-Pin Chen</dc:creator>
<dc:creator>Cheng-Ying Shiau</dc:creator>
<dc:creator>Pin-I Huang</dc:creator>
<dc:creator>I Chun Lai</dc:creator>
<dc:creator>Ling-Ming Tseng</dc:creator>
<dc:creator>Nicole Huang</dc:creator>
<dc:creator>Chia-Jen Liu</dc:creator>
<dc:date>2023-08-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Association of radiation dose to cardiac substructures with major ischaemic events following breast cancer radiotherapy</dc:title>
<dc:identifier>pmid:37585426</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad462</dc:identifier>
</item>
<item>
<title>Disparity in diagnosis and treatment of cardiovascular disease in women: a call to joint action from the European Society of Cardiology Patient Forum</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37585369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230817100713&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 16:ehad480. doi: 10.1093/eurheartj/ehad480. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37585369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230817100713&v=2.17.9.post6+86293ac">37585369</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad480>10.1093/eurheartj/ehad480</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37585369</guid>
<pubDate>Wed, 16 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mary Galbraith</dc:creator>
<dc:creator>Inga Drossart</dc:creator>
<dc:date>2023-08-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Disparity in diagnosis and treatment of cardiovascular disease in women: a call to joint action from the European Society of Cardiology Patient Forum</dc:title>
<dc:identifier>pmid:37585369</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad480</dc:identifier>
</item>





























</channel>
</rss>